Post-EHA 2026 Multiple Myeloma Highlights

Featuring presentations & discussions on selected Myeloma abstracts from the 31st Congress of the European Hematology Association (EHA).  

Chair: Karthik Ramasamy | Moderators: Cyrille Touzeau & Nisha Joseph

The Post-EHA 2026 Multiple Myeloma Highlights has been supported by CellCentric (Silver Sponsor). Supporters have no influence over the production of content.

Preliminary Agenda (subject to change)

Session 1: Latest in targeted immune modulation and cellular therapy

Arlocabtagene autoleucel, A GPRC5D-targeted CAR T-cell therapy for patients with relapsed/refractory multiple myeloma: Updated Phase 1 safety and efficacy results in patients with 1–3 prior regimens (Abstract S200) | Speaker: Susan Bal

CB-011, an allogeneic anti-BCMA CAR-T cell therapy with immune cloaking, for patients with relapsed/refractory multiple myeloma (CAMMOUFLAGE Phase 1 trial) (Abstract S201) | Speaker: Binod Dhakal

Safety and efficacy of iberdomide-based quadruplet for patients with newly diagnosed multiple myeloma: The IDEAL Phase I/II trial results (Abstract S199) | Speaker: Prashant Kapoor

Updated results of a Phase 1 first-in-human study of cemsidomide, a novel MONODAC® degrader, with dexamethasone (DEX) in patients with RRMM (Abstract PF763) | Speaker: Binod Dhakal

Panel discussion 

Session 2: Advances in T-cell engager monotherapy in smoldering myeloma & amyloidosis  

Phase 3 randomized trial of anselamimab demonstrates improvement in all-cause mortality in Κ light-chain amyloidosis (Abstract S206) | Speaker: Ashutosh Wechalekar

Initial efficacy and safety data from the Phase 1/2 LINKER-AL2 study of linvoseltamab (linvo) monotherapy in patients with relapsed or refractory (RR) systemic light chain (AL) amyloidosis (Abstract S208) | Speaker: Ashutosh Wechalekar 

Safety and efficacy of elranatamab as early intervention in patients with high-risk smoldering myeloma: First results from the Phase 2 ERASMM (EMN34) study (Abstract S205) | Speaker: Claudio Cerchione

Teclistamab improves depth of response and PFS versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: results from the Phase 2 ImmunoPRISM trial (Abstract LB5008) | Speaker: Omar Nadeem

Panel discussion 

Session 3: Recent progess in T-cell engager combination approaches in NDMM and RRMM

Teclistamab (tec) +/- lenalidomide (len) versus len alone as maintenance therapy post-transplant in newly diagnosed multiple myeloma (NDMM): Updated safety run-in (sri) results from EMN30/MAJESTEC-4 (Abstract S197) | Speaker: Niels van de Donk

High MRD negativity rates and prolonged PFS with belantamab mafodotin plus daratumumab, lenalidomide, and dexamethasone in transplant ineligible newly-diagnosed myeloma: Results of the BELA-DRD study (Abstract S204) | Speaker: Evangelos Terpos

Phase 3, randomized study of talquetamab (Tal) plus daratumumab (Dara) ± pomalidomide (Pom) vs dara plus pom and dexamethasone (DPD) in relapsed/refractory multiple myeloma (RRMM): MONUMENTAL-3 (Abstract S100) | Speaker: Meral Beksaç

MAJESTEC-9: A Phase 3 study of teclistamab monotherapy vs pomalidomide/bortezomib/dexamethasone or carfilzomib/dexamethasone (PVD/KD) in patients (PTS) with relapsed/refractory multiple myeloma (RRMM) (Abstract S195) | Speaker: Roberto Mina

Teclistamab plus daratumumab (TEC-DARA) in patients (PTS) with relapsed refractory multiple myeloma (RRMM): Analysis of MAJESTEC-3 based on cytogenetic and functional risk (Abstract S198) | Speaker: Rahul Banerjee

Panel discussion 

Conclusions and webinar close